Off-label prescribing is legal, common, and well-established in U.S. medicine — but it carries specific documentation, informed-consent, and liability considerations that longevity-focused prescribing raises in a particularly acute form.
This article describes general, publicly available information about the regulatory and legal framework for off-label prescribing in the United States. It is not legal advice for any specific clinical situation. Physicians should consult their institution's legal counsel, medical board guidance, and malpractice carrier for jurisdiction-specific requirements.
The FDA regulates how manufacturers may market a drug — it does not regulate how physicians may prescribe it. Once a drug is approved for any indication, a physician may lawfully prescribe it for any other use, at their clinical judgment, provided that use has a legitimate medical basis. This is standard, long-established medical practice, not a legal gray area — off-label prescribing is estimated to account for a substantial share of all outpatient prescriptions across specialties, not unique to longevity medicine.
Most off-label prescribing extends a drug to a related, well-studied disease indication (e.g., a beta-blocker for a related cardiac condition). Longevity-focused off-label use is different in kind: it targets aging itself, which the FDA does not recognize as a treatable indication at all — there is no regulatory pathway, and therefore no drug, that is or could currently be "approved for longevity." This makes every longevity-focused off-label prescription rest entirely on extrapolation from a different approved indication's evidence base (metformin's diabetes trials, rapamycin's transplant data) to an unapproved use.
Medical liability guidance generally emphasizes clear documentation of the clinical rationale for an off-label use, the evidence reviewed (including its limitations), and specific informed consent that the use is off-label and what alternatives exist. This documentation standard is not unique to longevity prescribing, but the evidence gaps involved — no approved indication, often no hard-outcome human trial at all — make thorough documentation particularly important from both a clinical-judgment and liability standpoint.
Off-label prescriptions are typically not covered by insurance for the off-label indication, a practical consideration for patients. Malpractice exposure for off-label prescribing generally turns on whether the use reflected sound clinical judgment supported by available evidence — not on the off-label status itself, which courts and medical boards have long recognized as a normal part of medical practice.
Off-label longevity prescribing is legal and clinically established practice, resting on the same general framework as any other off-label use — but it uniquely lacks any approved-indication anchor, since "aging" itself has no FDA pathway. Clear documentation of the evidence reviewed, informed consent, and awareness that insurance typically won't cover the off-label use are the practical considerations that follow from that gap.
This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.